Shares of Sientra Inc (NASDAQ:SIEN) have earned a consensus recommendation of “Buy” from the twelve brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $24.14.

A number of brokerages have commented on SIEN. Zacks Investment Research raised Sientra from a “sell” rating to a “hold” rating in a research report on Friday, November 16th. BidaskClub cut Sientra from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. Finally, Dougherty & Co began coverage on Sientra in a research report on Thursday, August 30th. They set a “buy” rating and a $31.00 price target for the company.

Shares of SIEN opened at $18.00 on Friday. Sientra has a one year low of $8.79 and a one year high of $26.79. The company has a quick ratio of 2.34, a current ratio of 2.77 and a debt-to-equity ratio of 0.36. The stock has a market cap of $509.07 million, a price-to-earnings ratio of -6.38 and a beta of -0.42.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported ($0.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.05). Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The firm had revenue of $16.90 million for the quarter, compared to analyst estimates of $16.66 million. During the same period in the prior year, the firm posted ($0.74) EPS. The business’s revenue was up 72.4% compared to the same quarter last year. As a group, equities research analysts expect that Sientra will post -3.05 earnings per share for the current year.

In other Sientra news, Director Timothy Haines sold 89,651 shares of Sientra stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the completion of the transaction, the director now owns 37,662 shares in the company, valued at approximately $811,992.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.00% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its stake in shares of Sientra by 5.5% during the 3rd quarter. BlackRock Inc. now owns 1,572,899 shares of the medical instruments supplier’s stock valued at $37,561,000 after buying an additional 82,312 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Sientra during the 2nd quarter valued at about $20,375,000. Vanguard Group Inc. raised its stake in shares of Sientra by 1.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock valued at $24,293,000 after buying an additional 14,422 shares during the last quarter. Millennium Management LLC raised its stake in shares of Sientra by 93.4% during the 2nd quarter. Millennium Management LLC now owns 858,206 shares of the medical instruments supplier’s stock valued at $16,744,000 after buying an additional 414,418 shares during the last quarter. Finally, Waddell & Reed Financial Inc. purchased a new position in shares of Sientra during the 2nd quarter valued at about $15,035,000. Institutional investors and hedge funds own 87.01% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Story: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.